ORTHOCELL LIMITED (ASX: OCC)
Health care · News and insights
Price unavailable
Latest OCC announcements
2026-11-10 · Health care
OCC: $0.595 +0.85% · MC: $155M
Orthocell issued one million unquoted options under an agreement for US marketing services, with vesting tied to the consultant’s continued engagement or a company trigger notice. Director John Van Der Wielen separately bought shares on market, increasing his holding to 727,741 shares; his existing options were unchanged.
Updated 2026-11-10 18:24
Sources
Appendix 3Y - John Van Der WielenOption Terms and ConditionsProposed issue of securities - OCCNotification regarding unquoted securities - OCCComments
2026-11-06 · Health care
OCC: $0.575 +3.60% · MC: $155M
At its AGM, Orthocell said October was its strongest month of U.S. Remplir sales since launch, with early November also showing encouraging momentum; the chair said sustaining the pace over the next six months could deliver a healthy top line at significant margins. The company reported FY2026 revenue growth of 45% and cash of approximately $39 million, while noting shareholder disappointment with recent share-price performance.
Updated 2026-11-06 16:23
Sources
AGM Addresses by Chair and Managing DirectorAmended ConstitutionComments
2026-11-03 · Health care
OCC: $0.570 +0.00% · MC: $155M
Marine Biomedical has received U.S. FDA clearance to market its PearlBone bone graft substitute for cleared indications, advancing it towards commercialisation. Orthocell holds a 12% stake and first right of refusal over global distribution rights, but any role in a launch depends on exercising those rights and agreeing commercial terms. The clearance adds a potential bone-repair product to Orthocell’s nerve and tendon portfolio; its U.S. Remplir sales also recently reached a record month, up 84% on the Q1 FY27 monthly average.
Updated 2026-11-03 10:11
Sources
Marine Biomedical Achieves FDA ClearanceComments
2026-11-02 · Health care
OCC: $0.570 +3.64% · MC: $155M
Orthocell sold 92 units of its Remplir nerve repair product in the US in October, generating $279,000 in revenue. Unit sales rose 84% from the monthly average in the first quarter of FY27. The company attributed the result to growing surgeon adoption, repeat use, a broader distributor network and expanded hospital access.
Updated 2026-11-02 10:24
Sources
Strongest U.S. Remplir Sales Month Since LaunchComments
Comments